Copy Link Print Information

Oxaliplatin

226 Cited Publications
Revisión del cliente

Based on 226 publication(s) in Google Scholar

Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza: 99.65%
  • No. CAS: 61825-94-3
  • Fòrmula: C8H14N2O4Pt
  • Peso molecular:397.29
  • Almacenamiento:

    4°C, protect from light

    * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

  • Oxaliplatin Chemical Structure
    Oxaliplatin Chemical Structure
  • Experimental Validation Results for Oxaliplatin
  • Experimental Validation Results for Oxaliplatin
  • Experimental Validation Results for Oxaliplatin
  • Experimental Validation Results for Oxaliplatin
  • Experimental Validation Results for Oxaliplatin
  • Experimental Validation Results for Oxaliplatin
No. CAS: 61825-94-3
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Oxaliplatin:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Oxaliplatin

More
Customer Validation & Images
In Vivo Efficacy StudyCell Proliferation/Viability AssayIF
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • IF

Ver todos los productos específicos de isoformas DNA/RNA Synthesis

More
Keywords
100 mg

Obtener un presupuesto En stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Oxaliplatin Chemical Structure
    Oxaliplatin Chemical Structure
    1/16
  • 1/16

    Oxaliplatin purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2024 Dec 3:78:101179. [Abstract]

    Customer Validation
     Oxaliplatin (100 nM-4 μM; 48 h) inhibits CEAhigh (AGS) and CEA-⁠/lo (xhGC1) gastric cancer cells, with IC50 values of 150 nM and 2.2 μM, respectively.

  • 1/16

    Oxaliplatin purchased from MedChemExpress. Usage Cited in: Nat Med. 2024 Mar;30(3):749-761. [Abstract]

    Customer Validation
     The relative cell viability of shCtl-, shNDUFB8-, and shCEMIP2-transfected cells was detected by XTT assay after paclitaxel plus gemcitabine treatment (A+G), single-agent 5-Fu (5-FU), and the FOLFIRINOX chemotherapy cocktail [FU+IRI+OXA: 5-FU+Irinotecan (SN-38) +Oxaliplatin (50 nM)] for 48h.

  • 1/16

    Oxaliplatin purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2023 Jan;20(1):51-64. [Abstract]

    Customer Validation
     Comparison of drug (Epirubicin hydrochloride, EPI; Daunorubicin hydrochloride, DNR; Vinorelbine ditartrate, VNR; Oxaliplatin, OXA; Vincristine, VCR; Artemisinin, ART; Colchicine, COL) cytotoxicity to TC1 cells at the indicated doses and time points measured with CCK-8 assays. R.U. (Relative unit) was calculated from the average O.D. values in each condition as the indicator of cell viability (n = 3).

  • 1/16

    Oxaliplatin purchased from MedChemExpress. Usage Cited in: Gastroenterology. 2021 Nov;161(5):1601-1614.e23. [Abstract]

    Customer Validation
     Bar graphs show the GI50 of 5-fluoruracil (48 h), irinotecan (48 h), gemcitabine (48 h), paclitaxel (48 h), and oxaliplatin (48 h) in PDAC cells in combination with bioactive hexapeptides (NTAIYY and PTTIYY) or controls (saline and NTAIYA).

  • 1/16

    Oxaliplatin purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2020 Nov;14(11):2894-2919. [Abstract]

    Customer Validation
     FOLFOX was administered as 6 mg/kg Oxaliplatin two hours before administration of 90 mg/kg Leucovorin and 50 mg/kg 5-Fluorouracil at day 1 and a repeat of 5‐Fluorouracil dosing on day 2. Weight loss of ODC-, CTRL-, and FOLFOX-treated mice over time of mice with DLD1 tumors.

  • 1/16

    Oxaliplatin purchased from MedChemExpress. Usage Cited in: Nat Med. 2019 Sep;25(9):1428-1441. [Abstract]

    Customer Validation
     Quantification of CD3+IFN-γ+ T cells in lung lobes taken from urethane-induced primary lung cancer models (n = 5 mice for SD group, n = 6 mice for all the other groups). Three coronal sections containing five pulmonary lobes from each mouse near the maximal diameters are quantified. Each dot represents one view field. A representative result from two independent experiments is shown.

  • Oxaliplatin